Federal Pharmaceutical was founded in 1990 and listed in Hong Kong in 2007. The stock code is 3933.HK, mainly engaged in the research and development, production and sales of drugs. After more than 30 years of development, Federal Pharmaceutical has formed a comprehensive pharmaceutical group with four major business segments: preparations, raw materials, biology, and animal welfare, and nine production and R&D entities. Its sales network covers the world and currently has more than 16,000 employees. Since its establishment, Federal Pharmaceuticals has been committed to providing high-quality products and services to the society and promoting high-quality development of the pharmaceutical industry. It is one of the leading comprehensive pharmaceutical companies in China.

Zhuhai Federal Pharmaceutical Co., Ltd. was registered and established in 1993. The factory was completed and put into production in 1998. Currently, production bases have been established in Sanzao Town and Nanshui Town, Jinwan District, Zhuhai City, covering a total area of ​​450,000 square meters and employees are about 2,700. people. After more than 20 years of development, it has become a high-tech modern comprehensive pharmaceutical enterprise integrating production and R&D.

The company's main products include more than 50 varieties of insulin, penicillin, cephalosporin, carat, and penem. Oral semi-synthetic penicillin workshop is currently a production workshop with a large production capacity of similar products in China, with an annual production capacity of more than 5,000 tons. The annual production capacity of the "Golden Feiyan" and "Silver Feiyan" brand products of the cephalosporin series and the carat series are about 1,000 tons. Products sold worldwide.

Federal Pharmaceuticals is a company that uses genetically engineered Pichia cerevisia expression technology to produce insulin products, and is also a company that has an insulin prefilled pen assembly line in China. In 2009, the second generation of insulin human insulin (Yusling) was launched. In 2016, the third generation of insulin analog insulin glargine (Yusling) was launched. In 2021, the insulin aspart was launched, and Federal Pharmaceutical became the same. Domestic companies with second and third generation insulin production capabilities. After the project reaches full production, the production capacity will reach 3 tons of raw materials and 300 million preparations, with an annual output value of more than 10 billion yuan.

Introducing intelligent manufacturing, Zhuhai Company is an enterprise that adds sterile operation robot intervention system to the sterile raw material industry. It uses robots instead of manual operation in A-level clean areas to ensure the quality of sterile drugs and reduce safety risks. The explored intelligent manufacturing has a profound impact on the quality assurance of sterile pharmaceuticals and the application of industrial intelligence.

Taking a diversified development path, Federal Peptide Beauty is a company that has created a polypeptide cosmetic raw material brand for skin care. Its main effects include whitening, firming, anti-wrinkle and anti-aging. In 2017, the use of peptide raw materials into finished cosmetics began, opening a new era of federal peptide beauty skin care.

In line with the international level, the quality system insists on international capacity building, and Zhuhai Company always puts quality work first. All series of products such as insulin and antibiotics have passed the domestic GMP compliance test. Amoxicillin and ampicillin raw materials have been subjected to German GMP certification inspections many times. Amoxicillin sodium, potassium clavulanate and other sterile raw materials have obtained the EU CEP certificate, and sterile raw materials such as ampicillin sodium and sulbactam sodium Together, we have successively passed the official joint GMP inspections of EDQM and Spain and other officials.

In the future, Federal Pharmaceutical will continue to promote industrial upgrading and innovative development, develop more safe and effective drugs, and make greater contributions to human health.